Shuanqiao ointment for clearing damp, reducing phlegm, burning fat, reducing weight and improving edema and preparation method of Shuanqiao ointment

Abstract

The invention belongs to the technical field of traditional Chinese medicines, mainly relates to a medicinal and edible cream formula and a preparation method thereof, and in particular relates to a Shuanqu cream for clearing damp and reducing phlegm, burning fat and reducing weight and improving edema and a preparation method thereof. The ointment comprises the following medicinal and edible medicinal materials in parts by weight: 10-12 parts of platycodon grandiflorum, 9-12 parts of pericarpium citri reticulatae, 15-20 parts of lotus leaves, 7-10 parts of agastache rugosus, 13-15 parts of poria cocos, 10-13 parts of exocarpium citri rubrum, 7-10 parts of amomum tsao-ko and 14-19 parts of corn stigma. Wherein the agastache rugosus and the amomum tsao-ko are subjected to supercritical CO2 extraction, and the platycodon grandiflorum, the pericarpium citri reticulatae, the poria cocos, the lotus leaves and the corn stigma are fermented The compound bacterial strain is prepared from bacillus coagulans TS346726 and kluyveromyces marxianus ATCC-36534, and the bacillus coagulans TS346726 and the kluyveromyces The prepared ointment has the effects of clearing damp, reducing phlegm, burning fat, reducing weight and improving edema.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine technology, and mainly relates to a medicinal and edible herbal paste and its preparation method, specifically to a water-based herbal paste for removing dampness and phlegm, reducing fat and weight and improving edema and its preparation method. Background Technology

[0002] Food-medicine homology pastes are ointments made from medicinal and edible ingredients based on traditional Chinese medicine theory. They combine dietary therapy and conditioning effects. Currently, most ointments and medicated pastes on the market have limited efficacy, often only having a single effect such as simply removing dampness or only targeting weight loss, making it difficult to meet multiple health needs at the same time. In view of this, this invention has developed a food-medicine homology paste that integrates multiple effects such as removing dampness and phlegm, reducing fat and weight, and improving edema. It aims to solve related health problems more comprehensively through the synergistic effect of multiple effects. Summary of the Invention

[0003] This invention relates to a medicinal and edible herbal paste and its preparation method. The core innovation lies in supercritical CO2 extraction of patchouli / amomum villosum and fermentation with a complex of bacteria including platycodon grandiflorum (TS346726 + Kluyveromyces martensii ATCC-36534). The research aims to improve the extraction rate of volatile oils (traditional methods result in losses >30%). CO2 extraction is chosen because it is green and non-thermal. One of the purposes of fermentation is to use the complex bacteria to disrupt cell walls and improve flavonoid utilization. Single and different combinations were screened, and multiple iterations confirmed that the polysaccharide yield at 30℃ / 37℃ in stages reached 30% (superior to 20% with single bacteria), and the body weight decreased by 25% (superior to 15%).

[0004] To address the aforementioned problems, this invention develops a medicinal and edible herbal paste. This paste uses Platycodon grandiflorus, Citrus reticulata peel, Nelumbo nucifera leaf, Pogostemon cablin, Poria cocos, Citrus reticulata peel, Amomum tsao-ko, and corn silk as raw materials. It is prepared through co-fermentation of Bacillus coagulans TS346726 and Kluyveromyces martensii ATCC-36534. The resulting herbal paste has the effects of removing dampness and phlegm, reducing fat and weight, and improving edema.

[0005] In a first aspect, the present invention provides a medicinal and edible herbal paste for dispelling dampness and phlegm, reducing fat and weight, and improving edema. The medicinal and edible herbs contained in the herbal paste include, by weight, 10-12 parts of Platycodon grandiflorus, 9-12 parts of Citrus reticulata peel, 15-20 parts of Nelumbo nucifera leaf, 7-10 parts of Pogostemon cablin, 13-15 parts of Poria cocos, 10-13 parts of Citrus reticulata peel, 7-10 parts of Amomum tsao-ko, and 14-19 parts of corn silk. Among them, Pogostemon cablin and Amomum tsao-ko are extracted by supercritical CO2 extraction, and Platycodon grandiflorus, Citrus reticulata peel, Poria cocos, Nelumbo nucifera leaf, and corn silk are fermented by compound strains. The compound strains include Bacillus coagulans TS346726 and Kluyveromyces martensii ATCC-36534.

[0006] Secondly, this invention provides a method for preparing a medicinal and edible herbal paste that dispels dampness and phlegm, reduces fat and weight, and improves edema. The specific preparation steps are as follows: S1. Raw material pretreatment: Accurately weigh 10-12g of Platycodon grandiflorus, 9-12g of dried tangerine peel, 15-20g of lotus leaf, 7-10g of patchouli, 13-15g of Poria cocos, 10-13g of tangerine peel, 7-10g of Amomum tsao-ko, and 14-19g of corn silk. Clean the above raw materials, dry them in an oven at low temperature and then pulverize them. S2, Supercritical CO2 extraction: Take the patchouli and cardamom prepared in step S1 and put them into a supercritical CO2 extraction device. Set the extraction parameters: pressure 30MPa, temperature 40℃, CO2 flow rate 20L / h, extraction time 2.5-3h. Separate and collect the volatile essential oil and the drug residue after extraction. S3. Activation and propagation of bacterial strains: Bacillus coagulans TS346726 was inoculated onto MRS agar medium and activated by aerobic culture at 37℃ for 18-22 h; the activated strain was picked and transferred to 800-1200 mL of MRS liquid medium and cultured at 37℃ with shaking at 180 rpm for 8-10 h to obtain Bacillus coagulans fermentation broth; Kluyveromyces martensii ATCC-36534 was inoculated onto yeast agar medium and activated by aerobic culture at 30℃ for 18-22 h; the activated strain was picked and transferred to 800-1200 mL of yeast liquid medium and cultured at 30℃ with shaking at 180 rpm for 8-10 h to obtain Kluyveromyces martensii fermentation broth.

[0007] S4, Fermentation and Inactivation Mix the prepared Platycodon grandiflorus, dried tangerine peel, Poria cocos, lotus leaf, and corn silk thoroughly. Add 20-24 mL of Bacillus coagulans fermentation broth and 20-24 mL of Kluyveromyces martensii fermentation broth, and stir thoroughly to moisten the material. First, ferment aerobically at 30℃ for 28-30 h, then raise the temperature to 37℃ and continue aerobic fermentation for another 28-30 h. After fermentation, add 3% H2O2 solution to the fermented product and stir well. Let it stand for 1 h to completely inactivate the bacteria, obtaining the inactivated fermented product.

[0008] S5. Gradient Extraction: Combine the inactivated fermentation product from step S4 with the extracted drug residue obtained in step S2, and perform gradient solvent extraction: Water extraction: Add 8 times the amount of deionized water to the combined materials, reflux at 90-95℃ for 1.5-2 hours, filter, and collect the water extract.

[0009] Alcohol extraction: Mix the filter residue after water extraction with orange peel evenly, add 6 times the amount of ethanol, and extract by ultrasonication at 50-55℃ for 35-40 minutes. Filter and collect the alcohol extract.

[0010] Merging: Combine the aqueous extract and the alcohol extract.

[0011] S6. Concentration and essential oil fusion: The combined extract obtained in S5 is concentrated under reduced pressure at 50℃ and -0.08MPa to recover ethanol and water, and concentrated to a clear paste with a relative density of 1.25 (50℃); then, the volatile essential oil collected in S2 is slowly added to the clear paste under stirring, and stirred at 300-350rpm for more than 15-20min to fully and evenly blend it, thus obtaining the medicinal and edible paste of the present invention.

[0012] Preferably, the ointment prepared by the present invention has the effects of removing dampness and phlegm, reducing fat and weight, and improving edema.

[0013] Preferably, in step S1 of the present invention, during drying, the Chinese medicine is first baked at a low temperature of 35-40℃ for 2-3 hours to lock in the volatile oil components, and then continuously dried at a medium temperature of 50-55℃ for 5-7 hours to accelerate the evaporation of moisture. Through the gradient temperature control process, efficient drying is achieved while retaining the medicinal components.

[0014] Preferably, in step S1 of the present invention, the Chinese medicine is pulverized to 100 mesh.

[0015] Preferably, the MRS agar medium used in step S3 of the present invention comprises the following components: 10.0 g casein peptone; 10.0 g beef extract; 5.0 g yeast extract; 20.0 g glucose; 1.0 g Tween 80; 5.0 g sodium acetate; 2.0 g triammonium citrate; 2.0 g K2HPO4; 0.2 g MgSO4·7H2O; 0.05 g MnSO4·H2O; 15.0 g agar; and 1000.0 mL distilled water.

[0016] Preferably, the concentration of the Bacillus coagulans fermentation broth in step S3 of the present invention is 3.2-3.5×10⁸ cfu / mL.

[0017] Preferably, the yeast agar culture medium used in step S3 of the present invention comprises the following components: 3.0g yeast extract; 3.0g malt extract; 5.0g peptone; 10.0g glucose; 20.0g agar; and 1000.0mL distilled water.

[0018] Preferably, the concentration of the Kluyveromyces martensii fermentation broth in step S3 of the present invention is 4.0-4.2×10⁸ cfu / mL.

[0019] Preferably, the volume fraction of the ethanol solution in step S4 of the present invention is 70%.

[0020] Preferably, the power of ultrasonic extraction in step S4 of the present invention is 300-350W.

[0021] The present invention has the following beneficial effects: 1. It is made from 8 carefully selected medicinal and edible ingredients that are scientifically combined to work synergistically to remove dampness and phlegm, reduce fat and weight, and promote diuresis and reduce swelling, making it suitable for the daily conditioning needs of various groups.

[0022] 2. In terms of process, supercritical CO2 extraction technology is used to capture volatile essential oils, combined with gradient water extraction-alcohol extraction and dual-strain compound fermentation process to efficiently extract and transform active ingredients, taking into account both efficacy and safety. Moreover, the process is mature and can be mass-produced.

[0023] 3. Supercritical CO2 extraction of patchouli / amom may utilize high-pressure (30MPa) non-thermal (40℃) conditions, taking advantage of the supercritical state of CO2 as a green solvent, to selectively dissolve and extract volatile oils (such as patchouli aldehyde and amomum tsao-ko), avoiding the high-temperature oxidative degradation (loss >30%) of traditional steam distillation, thus preserving the complete structure of heat-sensitive components and promoting the elimination of dampness and phlegm (such as inhibiting the endogenous generation of damp-heat and regulating lung and spleen function). The fermentation of compound bacteria is speculated to degrade the polysaccharide layer and fibrous structure of cell walls of Platycodon grandiflorus / lotus leaf through the synergistic effect of Bacillus coagulans producing protease / cellulase and Kluyveromyces marsupials producing glycosylase / esterase, releasing flavonoids (such as corn silk flavonoids) and polysaccharides (such as Poria cocos polysaccharides), improving the dissolution rate and intestinal absorption of these components (utilization rate increased by 30%), and regulating the intestinal microbiome through fermentation metabolites (such as short-chain fatty acids) (such as increasing the abundance of beneficial bacteria and inhibiting lipid-producing bacteria). Attached Figure Description

[0024] To more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0025] Figure 1 This is a comparison chart of paw swelling rates in rats from Examples 1-3, Comparative Examples 4-6, and Comparative Examples 10-16.

[0026] Figure 2 This is a comparison chart of the weight gain of mice before and after the experiment in Examples 1-3, Comparative Examples 4, Comparative Examples 7-8, and Comparative Examples 10-16.

[0027] Figure 3 This is a comparison chart of the fat coefficient of mice in Examples 1-3, Comparative Examples 4, Comparative Examples 7-8, and Comparative Examples 10-16.

[0028] Figure 4 , Figure 5 and Figure 6 This is a picture of the product obtained in Embodiment 1 of the present invention. Detailed Implementation

[0029] The following specific examples illustrate the implementation of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and various details in this specification can also be modified or changed based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that, unless otherwise specified, the following embodiments and features described therein can be combined with each other.

[0030] Platycodon grandiflorus, dried tangerine peel, lotus leaf, agastache rugosa, poria cocos, tangerine peel, cardamom, and corn silk were all purchased from Anhui Kangweifu Pharmaceutical Co., Ltd.; Bacillus coagulans TS346726 was purchased from Ningbo Taisto Biotechnology Co., Ltd.; and Kluyveromyces martensii ATCC-36534 was purchased from Shanghai Jiachu Bioengineering Co., Ltd.

[0031] Example 1

[0032] This embodiment provides a method for preparing a medicinal and edible herbal paste, the specific steps of which are as follows: S1. Raw material pretreatment: Accurately weigh 10g of Platycodon grandiflorus, 9g of Citrus reticulata peel, 15g of Nelumbo nucifera leaf, 7g of Pogostemon cablin, 13g of Poria cocos, 10g of Citrus reticulata peel, 7g of Amomum tsao-ko, and 14g of corn silk. After cleaning the above raw materials, perform gradient temperature-controlled drying. First, bake at a low temperature of 35℃ for 2 hours to lock in the volatile oil components, and then continue to dry at a medium temperature of 50℃ for 5 hours to accelerate the evaporation of moisture. This process achieves efficient drying while retaining the medicinal components. After drying, pulverize all Chinese medicines to 100 mesh for later use. S2, Supercritical CO2 Extraction: The patchouli and cardamom powders prepared in step S1 are added to a supercritical CO2 extraction apparatus. The extraction parameters were set as follows: pressure 30 MPa, temperature 40 °C, CO2 flow rate 20 L / h, and extraction was carried out continuously for 2.5 h. The volatile essential oil and the extracted drug residue were collected by the separation system. S3. Activation and Propagation of Bacillus coagulans TS346726 was inoculated onto MRS agar medium (components: 10.0g casein peptone, 10.0g beef extract, 5.0g yeast extract, 20.0g glucose, 1.0g Tween 80, 5.0g sodium acetate, 2.0g triammonium citrate, 2.0g K₂HPO₄, 0.2g MgSO₄·7H₂O, 0.05g MnSO₄·H₂O, 15.0g agar, 1000.0mL distilled water) and activated by aerobic incubation at 37℃ for 20h. Single colonies of the activated strain were then transferred to 800mL MRS liquid medium and incubated at 37℃ with shaking at 180rpm for 8h to obtain a concentration of 3.2×10⁻⁶. 8The fermentation broth of *Bacillus coagulans* with a concentration of CFU / mL was prepared. *Kluyveromyces martensii* ATCC-36534 was inoculated onto yeast agar medium (components: 3.0 g yeast extract, 3.0 g malt extract, 5.0 g peptone, 10.0 g glucose, 20.0 g agar, and 1000.0 mL distilled water), and activated by aerobic incubation at 30°C for 20 h. Single colonies of the activated culture were then transferred to 800 mL of yeast liquid medium and incubated at 30°C with shaking at 180 rpm for 8-10 h to obtain a concentration of 4.0 × 10⁻⁶ CFU / mL. 8 Max Kluyveromyces fermentation broth, cfu / mL. S4. Fermentation and Inactivation: Mix the powders of Platycodon grandiflorus, Citrus reticulata peel, Poria cocos, Nelumbo nucifera leaf, and corn silk prepared in step S1 evenly, add 20 mL of Bacillus coagulans fermentation broth and 20 mL of Kluyveromyces martensii fermentation broth, stir thoroughly to make the material evenly moist, first ferment aerobically at 30℃ for 28 h, then raise the temperature to 37℃ and continue aerobic fermentation for 28 h, after the fermentation is completed, add 3% H2O2 solution to the fermentation product and stir quickly evenly, let stand for 1 h to completely inactivate the bacteria, and obtain the inactivated fermentation product. S5. Gradient Extraction: Combine the inactivated fermentation product from step S4 with the extracted drug residue obtained from step S2, and extract using a gradient solvent method: First, add 8 times the amount of deionized water to the combined material, reflux at 90℃ for 1.5h, filter and collect the aqueous extract; then mix the filtered residue after water extraction with orange peel evenly, add 6 times the amount of 70% ethanol (volume fraction), and ultrasonically extract at 50℃ and 300W power for 35min, filter and collect the ethanol extract, and finally mix the aqueous extract and ethanol extract thoroughly for later use.

[0033] S6. Concentration and Essential Oil Fusion: The combined extract obtained in S5 is placed in a vacuum concentration apparatus and concentrated under reduced pressure at 50℃ and -0.08MPa, while simultaneously recovering ethanol and water, until the relative density of the concentrate reaches 1.25 (50℃), yielding a clear extract. Subsequently, the volatile essential oil collected in S2 is slowly added to the clear extract under continuous stirring at 300 rpm for 15 minutes to ensure that the essential oil and the clear extract are fully and evenly blended, thus obtaining the medicinal and edible homologous ointment of this invention. (See product image below.) Figure 4 , Figure 5 and Figure 6 , Figure 4 and Figure 5 These are two packaging options for the product.

[0034] Example 2

[0035] This embodiment provides a method for preparing a medicinal and edible herbal paste, the specific steps of which are as follows: S1. Raw material pretreatment: Accurately weigh 11g of Platycodon grandiflorus, 10g of Citrus reticulata peel, 17g of Nelumbo nucifera leaf, 8g of Pogostemon cablin, 14g of Poria cocos, 12g of Citrus reticulata peel, 8g of Amomum tsao-ko, and 17g of corn silk. After cleaning the above raw materials, perform gradient temperature-controlled drying. First, bake at a low temperature of 37℃ for 2-3 hours to lock in the volatile oil components, and then continue drying at a medium temperature of 52℃ for 6 hours to accelerate the evaporation of moisture. This process achieves efficient drying while retaining the medicinal components. After drying, pulverize all Chinese medicines to 100 mesh for later use. S2, Supercritical CO2 extraction: The patchouli and cardamom powder prepared in step S1 are put into a supercritical CO2 extraction device. The extraction parameters are set as follows: pressure 30MPa, temperature 40℃, CO2 flow rate 20L / h, and extraction is continued for 2.5h. The volatile essential oil and the extracted drug residue are collected separately through the separation system. S3. Activation and Propagation of Bacillus coagulans TS346726 was inoculated onto MRS agar medium (components: 10.0g casein peptone, 10.0g beef extract, 5.0g yeast extract, 20.0g glucose, 1.0g Tween 80, 5.0g sodium acetate, 2.0g triammonium citrate, 2.0g K₂HPO₄, 0.2g MgSO₄·7H₂O, 0.05g MnSO₄·H₂O, 15.0g agar, 1000.0mL distilled water) and activated by aerobic incubation at 37℃ for 20h. Single colonies of the activated strain were then transferred to 1000mL MRS liquid medium and incubated at 37℃ with shaking at 180rpm for 9h to obtain a concentration of 3.4×10⁻⁶. 8 The fermentation broth of *Bacillus coagulans* with a concentration of CFU / mL was prepared. *Kluyveromyces martensii* ATCC-36534 was inoculated onto yeast agar medium (components: 3.0 g yeast extract, 3.0 g malt extract, 5.0 g peptone, 10.0 g glucose, 20.0 g agar, and 1000.0 mL distilled water), and activated by aerobic incubation at 30°C for 20 h. Single colonies of the activated culture were then transferred to 1000 mL of liquid yeast medium and incubated at 30°C with shaking at 180 rpm for 9 h to obtain a concentration of 4.1 × 10⁻⁶ CFU / mL. 8 Max Kluyveromyces fermentation broth, cfu / mL. S4. Fermentation and Inactivation: Mix the powders of Platycodon grandiflorus, Citrus reticulata peel, Poria cocos, Nelumbo nucifera leaf, and corn silk prepared in step S1 evenly, add 22 mL of Bacillus coagulans fermentation broth and 22 mL of Kluyveromyces martensii fermentation broth, stir thoroughly to make the material evenly moist, first ferment aerobically at 30℃ for 29 h, then raise the temperature to 37℃ and continue aerobic fermentation for 29 h, after the fermentation is completed, add 3% H2O2 solution to the fermentation product and stir quickly and evenly, let stand for 1 h to completely inactivate the bacteria, and obtain the inactivated fermentation product. S5. Gradient Extraction: Combine the inactivated fermentation product from step S4 with the extracted drug residue obtained from step S2, and extract using a gradient solvent method: First, add 8 times the amount of deionized water to the combined material, reflux at 92℃ for 1.7h, filter and collect the aqueous extract; then mix the filtered residue after water extraction with orange peel evenly, add 6 times the amount of 70% ethanol, and ultrasonically extract at 52℃ and 320W for 37min, filter and collect the ethanol extract, and finally mix the aqueous extract and ethanol extract thoroughly for later use.

[0036] S6. Concentration and essential oil fusion: The combined extract obtained in S5 is placed in a vacuum concentration device and concentrated under reduced pressure at 50°C and -0.08MPa, while simultaneously recovering ethanol and water, until the relative density of the concentrate reaches 1.25 (50°C), resulting in a clear paste; then, the volatile essential oil collected in S2 is slowly added to the clear paste under continuous stirring, and stirred at 320rpm for 17min to ensure that the essential oil and the clear paste are fully and evenly fused, thus obtaining the medicinal and edible homologous paste of the present invention.

[0037] Example 3

[0038] This embodiment provides a method for preparing a medicinal and edible herbal paste, the specific steps of which are as follows: S1. Raw material pretreatment: Accurately weigh 12g of Platycodon grandiflorus, 12g of Citrus reticulata peel, 20g of Nelumbo nucifera leaf, 10g of Pogostemon cablin, 15g of Poria cocos, 13g of Citrus reticulata peel, 10g of Amomum tsao-ko, and 19g of corn silk. After cleaning the above raw materials, perform gradient temperature-controlled drying. First, bake at a low temperature of 40℃ for 3 hours to lock in the volatile oil components, and then continue to dry at a medium temperature of 55℃ for 7 hours to accelerate the evaporation of moisture. This process achieves efficient drying while retaining the medicinal components. After drying, pulverize all Chinese medicines to 100 mesh for later use. S2, Supercritical CO2 extraction: The patchouli and cardamom powder prepared in step S1 are put into a supercritical CO2 extraction device. The extraction parameters are set as follows: pressure 30MPa, temperature 40℃, CO2 flow rate 20L / h, and extraction is continued for 2.5h. The volatile essential oil and the extracted drug residue are collected separately through the separation system. S3. Activation and Propagation of Bacillus coagulans TS346726 was inoculated onto MRS agar medium (components: 10.0g casein peptone, 10.0g beef extract, 5.0g yeast extract, 20.0g glucose, 1.0g Tween 80, 5.0g sodium acetate, 2.0g triammonium citrate, 2.0g K₂HPO₄, 0.2g MgSO₄·7H₂O, 0.05g MnSO₄·H₂O, 15.0g agar, 1000.0mL distilled water) and activated by aerobic incubation at 37℃ for 22h. Single colonies after activation were transferred to 1200mL MRS liquid medium and incubated at 37℃ with shaking at 180rpm for 10h to obtain a concentration of 3.5×10⁻⁶.8 The fermentation broth of *Bacillus coagulans* with a concentration of CFU / mL was prepared. *Kluyveromyces martensii* ATCC-36534 was inoculated onto yeast agar medium (components: 3.0 g yeast extract, 3.0 g malt extract, 5.0 g peptone, 10.0 g glucose, 20.0 g agar, and 1000.0 mL distilled water), and activated by aerobic incubation at 30°C for 22 h. Single colonies of the activated culture were then transferred to 1200 mL of yeast liquid medium and incubated at 30°C with shaking at 180 rpm for 10 h to obtain a concentration of 4.2 × 10⁻⁶ CFU / mL. 8 Max Kluyveromyces fermentation broth, cfu / mL. S4. Fermentation and Inactivation: Mix the powders of Platycodon grandiflorus, Citrus reticulata peel, Poria cocos, Nelumbo nucifera leaf, and corn silk prepared in step S1 evenly, add 24 mL of Bacillus coagulans fermentation broth and 24 mL of Kluyveromyces martensii fermentation broth, stir thoroughly to make the material evenly moist, first ferment aerobically at 30℃ for 30 h, then raise the temperature to 37℃ and continue aerobic fermentation for 30 h. After the fermentation is completed, add 3% H2O2 solution to the fermentation product and stir quickly and evenly, let stand for 1 h to completely inactivate the bacteria, and obtain the inactivated fermentation product. S5. Gradient Extraction: Combine the inactivated fermentation product from step S4 with the extracted drug residue obtained from step S2, and extract using a gradient solvent method: First, add 8 times the amount of deionized water to the combined material, reflux at 95℃ for 2 hours, filter and collect the aqueous extract; then mix the filtered residue after water extraction with orange peel evenly, add 6 times the amount of 70% ethanol (volume fraction), and ultrasonically extract at 55℃ and 350W for 40 minutes, filter and collect the ethanol extract, and finally mix the aqueous extract and ethanol extract thoroughly for later use.

[0039] S6. Concentration and essential oil fusion: The combined extract obtained in S5 is placed in a vacuum concentration device and concentrated under reduced pressure at 50°C and -0.08MPa, while simultaneously recovering ethanol and water, until the relative density of the concentrate reaches 1.25 (50°C), resulting in a clear paste; then, the volatile essential oil collected in S2 is slowly added to the clear paste under continuous stirring, and stirred at 350rpm for 20min to ensure that the essential oil and the clear paste are fully and evenly fused, thus obtaining the medicinal and edible homologous paste of the present invention.

[0040] Comparative Example 1: No orange-red was added in step S5, and all other steps were the same as in Example 1.

[0041] Comparative Example 2: No cardamom was added in step S2, and all other steps were the same as in Example 1.

[0042] Comparative Example 3: No patchouli was added in step S2, and all other steps were the same as in Example 1.

[0043] Comparative Example 4: Corn silk was not added in step S4, and all other steps were the same as in Example 1.

[0044] Comparative Example 5: Except for step S4, which does not include dried tangerine peel, all other steps are the same as in Example 1.

[0045] Comparative Example 6: Except for the omission of Platycodon grandiflorus in step S4, all other steps are the same as in Example 1.

[0046] Comparative Example 7: Except for the absence of lotus leaves in step S4, all other steps are the same as in Example 1.

[0047] Comparative Example 8: Except for the absence of Poria cocos in step S4, all other steps are the same as in Example 1.

[0048] Comparative Example 9: The supercritical CO2 extraction process in step S2 was omitted, that is, patchouli and cardamom were directly extracted in a gradient without the addition of essential oils. All other steps were the same as in Example 1.

[0049] Comparative Example 10: The fermentation process was omitted, i.e., Bacillus coagulans TS346726 and Kluyveromyces martensii ATCC-36534 were not added, and all other steps were the same as in Example 1.

[0050] Comparative Example 11: Except for the absence of Bacillus coagulans TS346726 in step S4, all other steps were the same as in Example 1.

[0051] Comparative Example 12: Except for the absence of Kluyveromycin ATCC-36534 in step S4, all other steps were the same as in Example 1.

[0052] Comparative Example 13: In step S4, Bacillus coagulans TS346726 was replaced with Bacillus coagulans CICC-21735 (purchased from China Industrial Microbial Culture Collection Center), and all other steps were the same as in Example 1.

[0053] Comparative Example 14: In step S4, Kluyveromyces ATCC-36534 was replaced with Kluyveromyces CICC-1275 (purchased from China Industrial Microbial Culture Collection Center), and all other steps were the same as in Example 1.

[0054] Comparative Example 15: The water extraction process in step S5 was omitted, and all other steps were the same as in Example 1.

[0055] Comparative Example 16: The alcohol extraction process in step S5 was omitted, and all other steps were the same as in Example 1.

[0056] Study 1: Verification of the efficacy of the ointment of this invention in removing dampness and resolving phlegm. Animals: SPF-grade C57BL / 6 mice, half male and half female, weighing 20±2g, were purchased from Liaoning Changsheng Biotechnology Co., Ltd. The mice were acclimatized for 7 days in an environment with a temperature of 21-25℃, humidity of 50%-70%, and alternating light and dark cycles of 12h. During this period, the mice had free access to food and water.

[0057] Grouping: After 7 days of adaptive feeding, the mice were randomly divided into blank group, model group, Example 1-3 group, Comparative Example 1-3 group and Comparative Example 9-16 group, with 9 mice in each group.

[0058] Modeling: After grouping, mice in the blank group were allowed free access to food and water. The food was ordinary feed (purchased from Shulaibao Biotechnology Co., Ltd.), and the water was room temperature physiological saline. They were kept in the same environment as those in the adaptive feeding group. Except for the control group, all other groups of mice were fed a high-fat diet (formula: 20% sucrose, 15% lard, 1.2% cholesterol, 0.2% sodium cholate, 10% casein, 0.6% dicalcium phosphate, 0.4% limestone powder, 0.4% premix, and 52.2% basal diet), with free access to water and food. They were housed in the same environment as during the initial acclimatization period for 1 day. On the second day, the humidity was increased to 95% to create a high-humidity external environment and induce internal humidity. The two environments were alternated during the modeling period. Six times a week, mice were subjected to exhaustive swimming with weights (8% of their body weight in lead weights on their tails) to simulate qi deficiency symptoms. The swimming environment was a room temperature of 21-25℃ and a water temperature of 22-24℃, conducted in a tank measuring 65cm long, 35cm wide, 35cm high, and 25cm deep. Mice were removed from the tank after exhaustion, dried, and immediately gavaged after swimming to simulate spleen deficiency and dampness caused by dietary damage. On odd-numbered days, mice were given 4℃ saline solution, and on even-numbered days, they were given lard. The modeling was continued for 28 days.

[0059] Administration: After modeling, the corresponding ointment was administered by gavage to groups 1-3, 1-3 and 9-16 of Examples, at a dose of 300 mg / kg. No administration was given to the blank group and the model group. The administration was continued for 14 days.

[0060] Measurement of phlegm-dampness symptoms in mice: After administration, the mice in each group were scored according to the phlegm-dampness symptom assessment scale (see Table 1). The experimental results are shown in Table 2. Table 1

[0061]

[0062] Measurement of blood lipid levels in mice: After the phlegm-dampness symptom scoring was completed, blood was collected from each group of mice and placed in heparin sodium anticoagulant blood collection tubes. The blood was centrifuged at 3000 r / min for 10 min at room temperature to obtain serum. The levels of three blood lipid indicators, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C), were measured. The experimental results are shown in Table 3. Table 2

[0063]

[0064] Table 3

[0065] Table 2 is a comparison table of phlegm-dampness symptom scores in each group of mice. As shown in Table 2, the blank group mice had the lowest scores. Compared with the blank group mice, the model group mice had significantly higher scores, indicating that the model was successfully established. Compared with the model group mice, the scores of mice in Examples 1-3, Comparative Examples 1-3, and Comparative Examples 9-16 were all significantly lower. Moreover, the scores of mice in Examples 1-3 were significantly lower and close to those of the blank group mice. This indicates that the ointment of the present invention has the best effect in relieving phlegm-dampness symptoms and has significant effects in removing dampness and resolving phlegm.

[0066] Table 3 shows the comparison of blood lipid levels in each group of mice. As can be seen from Table 3, the levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol (nonHDL-C) in the blank group mice were all within the normal physiological range. Compared with the blank group mice, the three blood lipid indicators in the model group mice were significantly increased. Combined with the modeling process of phlegm-dampness symptoms, it shows that the phlegm-dampness state induced by high lipids and high dampness is accompanied by blood lipid metabolism disorder, and the modeling was successful. Compared with the model group mice, the blood lipid indicators of mice in Examples 1-3, Comparative Examples 1-3, and Comparative Examples 9-16 were significantly reduced, and the blood lipid levels of mice in Examples 1-3 were significantly lower than those in the comparative examples, and were closer to the normal levels of the blank group.

[0067] Since phlegm-dampness syndrome in Traditional Chinese Medicine is often accompanied by abnormal blood lipid metabolism in Western medicine, the improvement of blood lipid levels can indirectly confirm the relief of phlegm-dampness symptoms. This indicates that the ointment of this invention can not only directly reduce the phlegm-dampness symptom score, but also improve phlegm-dampness-related blood lipid disorders, further proving that it has the best effect in relieving phlegm-dampness symptoms and has significant dampness-removing and phlegm-resolving effects.

[0068] Study 2: Verification of the efficacy of the ointment of this invention in improving edema Animals: SPF-grade Wistar rats, half male and half female, weighing 200±20g, were purchased from Liaoning Changsheng Biotechnology Co., Ltd. The rats were acclimatized for 7 days in an environment with a temperature of 21-25℃, humidity of 50%-70%, and alternating light and dark conditions with 12h light exposure. During this period, the rats had free access to food and water.

[0069] Grouping: After 7 days of adaptive feeding, the rats were randomly divided into blank group, model group, positive control group (indomethacin), Example 1-3 group, comparative example 4-6 group and comparative example 10-16 group, with 9 rats in each group.

[0070] Modeling: After grouping, rats in the control group were injected with 0.1 mL of physiological saline in the left hind toe to simulate the physiological state without inflammatory stimulation. Except for the control group, rats in all other groups were injected with 0.1 mL of 1% carrageenan suspension in the left hind foot to induce inflammation. The carrageenan-induced inflammatory response was used to construct a paw swelling model.

[0071] Drug administration: 4 hours after modeling, the corresponding ointment was administered by gavage to groups 1-3, 4-6 and 10-16 of the comparative examples, at 180 mg / kg; the positive control group was administered by gavage indomethacin suspension (10 mg / kg, dissolved in 0.5% CMC-Na solution), and the blank group and the model group were administered the same volume of physiological saline.

[0072] Measurement: The volume of the right hind paw was measured using capillary amplification measurement before and 12 hours after inflammation induction. The swelling rate of the rats was calculated. The experimental results are as follows: Figure 1 As shown.

[0073] Calculation formula: Swelling rate (%) = (Post-inflammatory plantar volume - Pre-inflammatory plantar volume) / Post-inflammatory plantar volume × 100% Figure 1 This is a comparison chart of paw edema rates in rats from Examples 1-3, Comparative Examples 4-6, and Comparative Examples 10-16. Figure 1 It can be seen that the swelling rate of the blank group rats was 0, which is a normal physiological state; compared with the blank group rats, the swelling rate of the model group rats was significantly increased, indicating that the carrageenan-induced foot swelling model was successfully constructed; compared with the model group rats, the swelling rates of the positive control group, the Example 1-3 groups and each comparative group rats were significantly reduced, and the swelling rate of the Example 1-3 group rats was significantly lower than that of the positive control group, and also significantly lower than that of each comparative group, and was closest to the level of the blank group rats, indicating that the ointment of the present invention has the best effect in improving edema and has a significant effect in improving edema.

[0074] Explanation of the mechanism of reduced effect in the comparative group Comparative Example 4: The absence of corn silk resulted in the loss of its water-soluble flavonoids and polysaccharides, making it difficult to alleviate water retention, significantly increasing the swelling rate, and weakening the anti-swelling effect. Comparative Example 5: In the absence of tangerine peel, the spleen and stomach's function of transporting and transforming water and dampness was not enhanced, the water metabolism disorder was not improved, the swelling rate increased, and the swelling-reducing effect was weakened; Comparative Example 6: Without Platycodon grandiflorus, the function of regulating water metabolism in the lungs was not activated, the efficiency of fluid excretion decreased, the swelling rate increased, and the anti-swelling effect was weakened; Comparative Example 10: After the fermentation was cancelled, the strain could not degrade the macromolecules of the raw materials (such as Poria cocos polysaccharide), the generation of small molecule diuretic active ingredients was insufficient, the water retention was not effectively relieved, and the swelling rate was close to that of the model group. Comparative Example 11: After the absence of Bacillus coagulans TS346726, its enzyme production and degradation of macromolecules of raw materials were lost, the content of small molecule diuretic components was insufficient, the swelling rate increased, and the swelling-reducing effect was weakened. Comparative Example 12: After the absence of Kluyveromyces martensii ATCC-36534, the amount of diuretic derivatives produced by its metabolism was insufficient, the auxiliary effect of water excretion was weakened, the swelling rate increased, and the anti-swelling effect was weakened. Comparative Example 13: The enzyme activity of the replacement strain was much lower than that of the original strain, the degradation efficiency of the raw material macromolecules was low, the release of small molecule diuretic components was insufficient, and the swelling effect was increased. Comparative Example 14: The replacement strain had poor metabolic activity, produced less diuretic derivatives, weakened water metabolism regulation, increased swelling rate, and weakened anti-swelling effect; Comparative Example 15: After removing water extraction, the water-soluble diuretic components (polysaccharides and flavonoids) in Poria cocos and corn silk were not effectively extracted, the core diuretic components were missing, the swelling rate increased significantly, and the swelling-reducing effect was weakened. Comparative Example 16: After removing the alcohol extraction, some fat-soluble auxiliary diuretic components were not extracted, the auxiliary regulatory effect of water metabolism was weakened, and the anti-edema effect was weakened.

[0075] Study 3: Verification of the efficacy of the ointment of this invention in improving edema Animals: SPF-grade male C57BL / 6 mice, weighing 20±2g, were purchased from Liaoning Changsheng Biotechnology Co., Ltd. The mice were acclimatized for 7 days in an environment with a temperature of 21-25℃, humidity of 50%-70%, and alternating light and dark conditions with 12h light exposure. During this period, the mice had free access to food and water.

[0076] Grouping: After 7 days of adaptive feeding, mice were randomly divided into blank group, model group, Example 1-3 group, comparative example 4 group, comparative example 7-8 group and comparative example 10-16 group, with 9 mice in each group.

[0077] Modeling: Mice in the control group were fed a normal diet (purchased from Shulaibao Biotechnology Co., Ltd.), while mice in other groups were fed a high-fat diet (formula: 20% sucrose, 15% lard, 1.2% cholesterol, 0.2% sodium cholate, 10% casein, 0.6% dicalcium phosphate, 0.4% limestone powder, 0.4% premix, and 52.2% basal diet) for 56 days to induce obesity in mice and establish an obesity model.

[0078] Administration: During the modeling period, the corresponding ointment was administered by gavage to groups 1-3, 4, 7-8 and 10-16 daily, at a dose of 300 mg / kg; the blank group and the model group were not administered the ointment, but were administered the ointment after feeding; once a day for 56 consecutive days.

[0079] Measurement of mouse weight change: The weight of the mice was measured and recorded before and after the experiment. The weight change, i.e., the weight gain, was calculated (weight gain = weight after the experiment - weight before the experiment). The experimental results are shown in Table 4 and... Figure 2 As shown.

[0080] Determination of mouse adipose tissue coefficient: After the weight change experiment, mice were sacrificed, and subcutaneous, epididymal, and perirenal white adipose tissue was collected. Blood was blotted with filter paper, and the tissue was weighed. The total weight of the subcutaneous, epididymal, and perirenal white adipose tissue (hereinafter referred to as total adipose tissue weight) was recorded, and the adipose tissue coefficient was calculated. The experimental results are as follows: Figure 3 As shown.

[0081] Fat coefficient = (Total weight of small adipose tissue / Mouse body weight) × 100% Table 4

[0082] Table 3 shows the comparison of the body weight of mice in each group before and after the experiment. Figure 2 This is a comparison chart of the weight gain of mice in Examples 1-3, Comparative Examples 4, Comparative Examples 7-8, and Comparative Examples 10-16 before and after the experiment. It can be seen that compared with the control group, the weight gain of the model group mice was significantly higher, indicating successful model establishment. Compared with the model group mice, the weight gain of mice in Examples 1-3, Comparative Examples 4, Comparative Examples 7-8, and Comparative Examples 10-16 was significantly lower, with the lowest weight gain in Examples 1-3. This indicates that the ointment of the present invention can effectively intervene in the abnormal accumulation of body fat caused by a high-fat diet, achieving a weight loss effect.

[0083] More importantly, Figure 3 This is a comparison chart of the adipose tissue coefficients of mice in Examples 1-3, Comparative Examples 4, Comparative Examples 7-8, and Comparative Examples 10-16. It can be seen that compared with the control group, the adipose tissue coefficient of the model group mice was significantly higher, indicating successful model establishment. Compared with the model group mice, the adipose tissue coefficients of mice in Examples 1-3, Comparative Examples 4, Comparative Examples 7-8, and Comparative Examples 10-16 all decreased to varying degrees, with the lowest adipose tissue coefficient in Examples 1-3. This significant decrease directly proves the "fat-reducing" effect of the ointment (i.e., reducing the formation and storage of adipose tissue).

[0084] In summary, under long-term high-fat diet induction, the ointment of this invention significantly inhibits pathological weight gain (weight loss / weight control) by eliminating the accumulation of excess fat (fat reduction), demonstrating excellent efficacy in preventing obesity and reducing fat. The ointment of this invention is highly effective in reducing fat and achieving weight loss.

[0085] Explanation of the mechanism by which the fat-burning and weight-loss effects of each ratio are weakened Comparative Example 4: The flavonoids in corn silk can inhibit fat synthesis enzymes and promote cholesterol excretion. When they are missing, fat synthesis increases and excretion decreases, leading to increased fat accumulation in the body and a significant reduction in fat-reducing effects.

[0086] Comparative Example 6: Lotus leaf is the core ingredient for fat reduction. The lotus leaf alkaloid it contains can inhibit lipase activity and reduce fat absorption. After its absence, the fat absorption inhibition effect is lost, the amount of fat accumulation increases, so the fat coefficient increases significantly and the fat reduction effect is weakened.

[0087] Comparative Example 7: Poria can regulate intestinal flora and promote fat metabolism, while also strengthening the spleen and reducing phlegm and dampness (phlegm and dampness are highly correlated with fat accumulation). When it is missing, intestinal flora becomes disordered, fat metabolism efficiency decreases, and the internal generation of phlegm and dampness exacerbates fat accumulation, thus weakening the fat-reducing and weight-loss effects.

[0088] Comparative Example 10: Fermentation strains can degrade macromolecular components (such as Poria cocos polysaccharides) in raw materials into small molecule active substances, thereby improving the absorption and utilization rate of fat-reducing components; after the fermentation is cancelled, the fat-reducing active components are not effectively converted, the utilization rate is extremely low, the fat-reducing effect is basically lost, and the fat coefficient is close to that of the model group.

[0089] Comparative Example 11: Bacillus coagulans strain TS346726 can produce enzymes to degrade the macromolecular components of raw materials such as Platycodon grandiflorus and Poria cocos, generating small molecule active substances that promote fat metabolism; when it is missing, the degradation of macromolecules in the raw materials is insufficient, the content of fat-reducing active ingredients is reduced, and the fat-reducing and weight-loss effects are weakened.

[0090] Comparative Example 12: The metabolism of Kluyveromyces martensii ATCC-36534 can produce components such as sugar alcohols and flavonoid derivatives that help regulate lipid metabolism; when these derivatives are missing, the production of such derivatives is insufficient, the lipid metabolism regulation effect is weakened, and the lipid-reducing effect is not as good as that of the Example Group.

[0091] Comparative Example 13: The enzyme activity of the replacement strain was much lower than that of the original strain, the degradation efficiency of the raw material macromolecules was low, the release of fat-reducing small molecule active ingredients was insufficient, and the fat-reducing and weight-loss effects were weaker than those of the Example Group.

[0092] Comparative Example 14: The replacement strain had poor metabolic activity, produced less derivatives that help regulate lipid metabolism, weakened the lipid metabolism regulation effect, and was inferior to the fat reduction and weight loss effect of the Example group.

[0093] Comparative Example 15: Water extraction can extract core fat-reducing components such as Poria cocos polysaccharides and water-soluble flavonoids from corn silk; after the removal of these components, they were not effectively extracted, resulting in the loss of core fat-reducing substances, increased fat accumulation, and weakened efficacy.

[0094] Comparative Example 16: Alcohol extraction can extract fat-soluble fat-reducing components such as lotus leaf alkaloids and platycodon saponins; after removal, these components are lost, the fat absorption inhibition and metabolism promotion effects are weakened, and the fat-reducing and weight-loss effects are reduced.

[0095] During the research and development of this invention, through literature review and parameter iteration experiments, we unexpectedly discovered that supercritical CO2 extraction of patchouli / amom can increase the yield of volatile oils by 35% (superior to steam distillation by 25%), while fermentation with compound bacteria (Bacillus coagulans TS346726 + Kluyveromyces martensii ATCC-36534) further improves the utilization rate of flavonoids / polysaccharides by 30% (superior to single bacteria by 20%). We screened steam / solvent extraction and single bacteria / different combinations, and iterated multiple times to confirm that 30MPa / 40℃ and staged 30℃ / 37℃ were the optimal values, leading to an unexpected synergistic leap: a 25% reduction in body weight and a decrease in body fat percentage in an obesity model ( Figure 3 The effect was 15-20% higher than the control group, while conventional replacements (such as no fermentation or single bacteria, control group 10-14) only achieved partial effects; this unexpected discovery revealed that only this specific combination of processes can trigger the overall synergistic effect of active ingredients.

[0096] The above-described embodiments are merely illustrative of specific implementations of the present invention, and while the descriptions are detailed, they should not be construed as limiting the scope of protection of the present invention. It should be noted that for those skilled in the art, any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention should be considered equivalent substitutions and are included within the scope of protection of the present invention.

Claims

1. A compound microbial agent, characterized in that, The compound microbial agent includes Bacillus coagulans TS346726 and Kluyveromyces marxianus ATCC-36534, and is used for fermenting a mixture of lycoris, dried orange peel, tuckahoe, lotus leaf and corn silk; the fermentation conditions of the compound microbial agent are as follows: first, aerobic fermentation at 30 DEG C for 28-30 h, and then aerobic fermentation at 37 DEG C for 28-30 h, and inactivation after fermentation.

2. A water-based paste for eliminating dampness and phlegm, reducing fat and weight, and improving edema, characterized in that: The paste contains the medicinal materials with the same origin as food according to weight parts, including lycoris 10-12 parts, dried orange peel 9-12 parts, lotus leaf 15-20 parts, agastache 7-10 parts, tuckahoe 13-15 parts, orange red 10-13 parts, cardamom 7-10 parts, and corn silk 14-19 parts; wherein the agastache and cardamom are extracted by supercritical CO2, and the lycoris, dried orange peel, tuckahoe, lotus leaf and corn silk are fermented by the compound microbial agent of claim 1.

3. The preparation method of the water-based paste for eliminating dampness, resolving phlegm, reducing fat and weight, and improving edema according to claim 2, characterized in that: The specific configuration method of the paste is as follows: S1, raw material pretreatment: accurately take lycoris 10-12 g, dried orange peel 9-12 g, lotus leaf 15-20 g, agastache 7-10 g, tuckahoe 13-15 g, orange red 10-13 g, cardamom 7-10 g, and corn silk 14-19 g, wash the above raw materials clean, dry them in an oven at low temperature and crush them; S2, supercritical CO2 extraction: take the agastache and cardamom prepared in step S1 and put them into a supercritical CO2 extraction device, set the extraction parameters: pressure 30 MPa, temperature 40 DEG C, CO2 flow rate 20 L / h, extraction time 2.5-3 h, and separate and collect the volatile essential oil and the drug residue after extraction; S3, strain activation and expansion culture: inoculate Bacillus coagulans TS346726 into MRS agar medium, and cultivate aerobically at 37 DEG C for 18-22 h for activation; pick the activated strain, transfer it into 800-1200 mL MRS liquid medium, and cultivate aerobically at 37 DEG C and 180 rpm for 8-10 h to prepare Bacillus coagulans fermentation liquor; inoculate Kluyveromyces marxianus ATCC-36534 into yeast agar medium, and cultivate aerobically at 30 DEG C for 18-22 h for activation; pick the activated strain, transfer it into 800-1200 mL yeast liquid medium, and cultivate aerobically at 30 DEG C and 180 rpm for 8-10 h to prepare Kluyveromyces marxianus fermentation liquor; S4, fermentation and inactivation: mix the lycoris, dried orange peel, tuckahoe, lotus leaf and corn silk prepared in step S1 evenly, add 20-24 mL Bacillus coagulans fermentation liquor and 20-24 mL Kluyveromyces marxianus fermentation liquor, and stir well to make the materials wet; first, aerobic fermentation at 30 DEG C for 28-30 h, then continue aerobic fermentation at 37 DEG C for 28-30 h; after fermentation, add 3% H2O2 solution to the fermented material and stir evenly, stand for 1 h to completely inactivate the bacteria, and obtain the inactivated fermented material; S5, gradient extraction: combine the inactivated fermented material of step S4 and the drug residue after extraction of step S2, and extract by using gradient solvent: Water extraction: 8 times the amount of deionized water was added to the above-mentioned combined material, and reflux extraction was carried out at 90-95°C for 1.5-2h, and then filtration was performed, and the water extract was collected; Alcohol extraction: the filter residue after water extraction was mixed with red citrus, 6 times the amount of ethanol was added, and ultrasonic extraction was carried out at 50-55°C for 35-40min, and then filtration was performed, and the alcohol extract was collected and combined with the water extract; S6, concentration and essential oil fusion: the combined extract obtained in S5 was concentrated under reduced pressure at 50°C and -0.08MPa, and ethanol and water were recovered, and the concentration was carried out to a clear paste with a relative density of 1.25 (50°C); the volatile essential oil collected in S2 was slowly added to the clear paste under stirring, and stirring was carried out at a speed of 300-350rpm for 15-20min or more, so that it was fully and uniformly fused, and thus a homoeopathy ointment of the application was obtained.

4. The preparation method of the water-based paste for eliminating dampness, resolving phlegm, reducing fat and weight, and improving edema according to claim 3, characterized in that: In the step S1, the drying was carried out at a low temperature of 35-40°C for 2-3h to lock the volatile oil components, and then the drying was continuously carried out at a medium temperature of 50-55°C for 5-7h, and in the step S1, the crushing treatment was carried out to 100 mesh.

5. The preparation method of the water-based paste for eliminating dampness, resolving phlegm, reducing fat and weight, and improving edema according to claim 3, characterized in that: The MRS agar medium used in the step S3 has the following components: casein peptone 10.0g; beef extract 10.0g; yeast extract 5.0g; glucose 20.0g; Tween 80 1.0g; sodium acetate 5.0g; triammonium citrate 2.0g; K2HPO4 2.0g; MgSO4·7H2O 0.2g; MnSO4·H2O 0.05g; agar 15.0g; distilled water 1000.0mL.

6. The preparation method of the water-based paste for eliminating dampness, resolving phlegm, reducing fat and weight, and improving edema according to claim 3, characterized in that: The yeast agar medium used in the step S3 has the following components: yeast extract 3.0g; malt extract 3.0g; peptone 5.0g; glucose 10.0g; agar 20.0g; distilled water 1000.0mL. The concentration of the Bacillus coagulans fermentation broth in the step S3 was 3.2-3.5×108cfu / mL.

7. The preparation method of the water-based paste for eliminating dampness, resolving phlegm, reducing fat and weight, and improving edema according to claim 3, characterized in that: The concentration of the Kluyveromyces marxianus fermentation broth in the step S3 was 4.0-4.2×108cfu / mL.

8. The preparation method of the water-based paste for eliminating dampness, resolving phlegm, reducing fat and weight, and improving edema according to claim 3, characterized in that: The volume fraction of the ethanol solution in the step S5 was 70%.

9. The preparation method of the water-based paste for eliminating dampness, resolving phlegm, reducing fat and weight, and improving edema according to claim 3, characterized in that: The ultrasonic extraction power in the step S5 was 300-350W.

10. The preparation method of the water-based paste for eliminating dampness, resolving phlegm, reducing fat and weight, and improving edema according to claim 3, characterized in that: ​

Images